Cesca Therapeutics (KOOL) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Cesca Therapeutics Reports Third Quarter Fiscal 2015 Results
June 23, 2015 4:05 PM EDTCompany Receives US FDA Approval for Its IDE Submission to the FDA for a Phase III Pivotal Clinical Trial for the Treatment of Patients With Critical Limb Ischemia (CLI)
Management Will Hold a Conference Call Today at 2:00pm Pacific (5:00pm Eastern)
RANCHO CORDOVA, Calif., June 23, 2015 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (Nasdaq: KOOL), an autologous cell-based regenerative medicine company, today reported financial results for the third quarter of fiscal 2015 and provided an update on its progress.
"We made strides in several key areas," said Robin C. Stracey, Chief... More
Cesca Therapeutics Reports Third Quarter Fiscal 2015 Results
June 23, 2015 4:05 PM EDTCompany Receives US FDA Approval for Its IDE Submission to the FDA for a Phase III Pivotal Clinical Trial for the Treatment of Patients With Critical Limb Ischemia (CLI)
Management Will Hold a Conference Call Today at 2:00pm Pacific (5:00pm Eastern)
RANCHO CORDOVA, Calif., June 23, 2015 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (Nasdaq: KOOL), an autologous cell-based regenerative medicine company, today reported financial results for the third quarter of fiscal 2015 and provided an update on its progress.
"We made strides in several key areas," said Robin C. Stracey, Chief... More
